It's a bit of a leap to think MJFF is actively involved in P2 sponsorship or any other meaningful way, although I wish it were the case. Missling's statement could mean they gave MJFF feedback on their decision on P2 trial design because of MJFF's prior sponsorship and recognition of MJFF's influence in PDD research. Anavex's SAB clout easily outweighs any constructive input MJFF may be capable of providing.